Francisco Diaz-Mitoma is a co-founder and chief medical officer of VBI Vaccines Inc. (VBIV, Nasdaq), a Canadian company with headquarters in Cambridge, Mass., main research operations in Ottawa and an FDA and EMA compliant vaccine manufacturing facility in Rehovot, Israel. Francisco is a former professor at the Faculty of Medicine, University of Ottawa and at the Northern Ontario School of Medicine. He led the Department of Laboratory medicine and Pathology at the Children’s Hospital of Eastern Ontario in Ottawa and was the founding CEO of the Health Sciences North Research Institute in Sudbury, Ontario. Francisco’s research has been published in more than 140 peer-reviewed journals and has been involved in the preclinical and clinical development of several licensed vaccines. His current portfolio includes phase one to phase 3 pivotal studies for both prophylactic and therapeutic vaccines for Hepatitis B, cytomegalovirus, Glioblastoma multiforme and COVID19 vaccine candidates. Recently, the 3-antigen Hepatitis B vaccine, PreHevbrio, was approved by FDA.